Trevi Therapeutics Stock EBITDA
| TRVI Stock | USD 4.36 0.24 5.83% |
Trevi Therapeutics fundamentals help investors to digest information that contributes to Trevi Therapeutics' financial success or failures. It also enables traders to predict the movement of Trevi Stock. The fundamental analysis module provides a way to measure Trevi Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Trevi Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -30.4 M | -31.9 M |
Trevi | EBITDA |
Trevi Therapeutics Company EBITDA Analysis
Trevi Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Trevi Therapeutics EBITDA | (33.8 M) |
Most of Trevi Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Trevi Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Trevi EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Trevi Therapeutics is extremely important. It helps to project a fair market value of Trevi Stock properly, considering its historical fundamentals such as EBITDA. Since Trevi Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Trevi Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Trevi Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Trevi Ebitda
Ebitda |
|
According to the company disclosure, Trevi Therapeutics reported earnings before interest,tax, depreciation and amortization of (33.8 Million). This is 103.85% lower than that of the Pharmaceuticals sector and 133.75% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.87% higher than that of the company.
Trevi EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Trevi Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Trevi Therapeutics could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics of similar companies.Trevi Therapeutics is currently under evaluation in ebitda category among its peers.
Trevi Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Trevi Therapeutics from analyzing Trevi Therapeutics' financial statements. These drivers represent accounts that assess Trevi Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Trevi Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 43.7M | 17.9M | 124.6M | 132.7M | 119.4M | 63.2M | |
| Enterprise Value | 12.9M | (4.3M) | 121.2M | 101.6M | 116.9M | 64.4M |
Trevi Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Trevi Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Trevi Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Trevi Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Trevi Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Trevi Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Trevi Therapeutics' value.| Shares | Ally Bridge Group (ny) Llc | 2024-09-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | State Street Corp | 2024-09-30 | 952.9 K | Rosalind Advisors, Inc. | 2024-09-30 | 750 K | Woodline Partners Lp | 2024-09-30 | 606.2 K | Silverarc Capital Management, Llc | 2024-09-30 | 482.6 K | Northern Trust Corp | 2024-09-30 | 433.6 K | Landscape Capital Management,llc | 2024-09-30 | 424.7 K | Longwood Capital Partners Llc | 2024-09-30 | 290.5 K | Nea Management Company, Llc | 2024-09-30 | 11.4 M | Rubric Capital Management Lp | 2024-09-30 | 5 M |
Trevi Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 303.81 M | ||||
| Shares Outstanding | 89.37 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 70.42 % | ||||
| Number Of Shares Shorted | 4.66 M | ||||
| Price To Book | 6.24 X | ||||
| EBITDA | (33.8 M) | ||||
| Net Income | (29.07 M) | ||||
| Cash And Equivalents | 77.86 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 1.34 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 5.18 X | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (31.71 M) | ||||
| Short Ratio | 1.30 X | ||||
| Earnings Per Share | (0.44) X | ||||
| Target Price | 9.81 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 368.19 M | ||||
| Total Asset | 89.4 M | ||||
| Retained Earnings | (239.13 M) | ||||
| Working Capital | //window.location = "/error404.html"; |